Iovance Biotherapeutics (IOVA) stock
Last close $6.90 on 2026-11-20 (-5.61%) · Sector: Healthcare
Iovance Biotherapeutics is a healthcare company that develops and sells cancer immunotherapies, which are treatments that use a patient's own immune cells to fight tumors. It makes money from its treatment sales and related revenue, while spending heavily on research and development to find new therapies.
Revenue has grown 52.0% over the past year and quarterly losses have narrowed, with the latest quarter showing a small net loss of $0.02 billion. The stock returned 216.5% over the past year versus 5.7% for the S&P 500, so it has beaten the broader market. Shares are 55.1% below their 52-week high and trade 38.5% below the 50-day average, though they sit 10.8% above the 200-day average. Earnings releases have caused big moves, with the stock rising after 2 and falling after 2 of its last four reports.
Key numbers
- Market cap: $3.1B
- Revenue (last 12 months): $0.38B
- Revenue growth: +52.0%
- Gross margin: 51.9%
- Operating margin: -57.9%
- P/S: 8.3
- Debt to equity: 0.00
- Current ratio: 5.00
Quality score
Overall 55/100 · growth 72 · profitability 0 · financial health 92 · value None
Performance and risk
1-year return +216.5% vs S&P 500 +5.7% · volatility 108.3% (S&P 500 14.3%) · largest drop -53.6% · beta 1.61
Stock move the day after earnings
- 2026-02-24: +30.8%
- 2026-05-07: -13.2%
- 2026-08-06: +43.1%
- 2026-11-05: -11.0%
Insider trades (12 months)
Bought $0.0M · sold $0.0M
IOVA stock research · IOVA options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.